CD123 overexpression in AML blasts and LSCs is associated with higher blast counts at diagnosis, poorer CR, and survival (127, 128), thereby establishing CD123 as a promising therapeutic target in AML. This evidence concerns the gene IL3RA and acute myeloid leukemia.